The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

The oncolytic adenovirus Delta24-RGD represents a new promising therapeutic agent for patients with a malignant glioma and is currently under investigation in clinical phase I/II trials. Earlier preclinical studies showed that Delta24-RGD is able to effectively lyse tumor cells, yielding promising r...

Full description

Bibliographic Details
Main Authors:	Anne Kleijn, Jenneke Kloezeman, Elike Treffers-Westerlaken, Giulia Fulci, Sieger Leenstra, Clemens Dirven, Reno Debets, Martine Lamfers
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4035348?pdf=render

Similar Items

Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma
by: Rutger K. Balvers, et al.
Published: (2014-08-01)

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity
by: Anne Kleijn, et al.
Published: (2017-06-01)

Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
by: Hong Jiang, et al.
Published: (2014-01-01)

Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
by: Eftychia Stavrakaki, et al.
Published: (2021-02-01)

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
by: Naiara Martínez-Vélez, et al.
Published: (2019-05-01)

Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
by: Federica Fabro, et al.
Published: (2022-01-01)

Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus
by: Ahmed Abdullah Al-Zaher, et al.
Published: (2018-03-01)

Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
by: Ioannis Ntafoulis, et al.
Published: (2022-07-01)

The Multifaceted Role of Macrophages in Oncolytic Virotherapy
by: Laura Hofman, et al.
Published: (2021-08-01)

Oncolytic Adenoviruses for Cancer Therapy
by: Lorella Tripodi, et al.
Published: (2021-03-01)

Oncolytic Adenovirus in Cancer Immunotherapy
by: Malin Peter, et al.
Published: (2020-11-01)

Concepts in Oncolytic Adenovirus Therapy
by: Klaus Mantwill, et al.
Published: (2021-09-01)

A Renaissance for Oncolytic Adenoviruses?
by: Paola Blanchette, et al.
Published: (2023-01-01)

Oncolytic Adenoviruses in Cancer Treatment
by: Ramon Alemany
Published: (2014-02-01)

Oncolytic Adenoviruses in Gastrointestinal Cancers
by: Raquel T. Yokoda, et al.
Published: (2018-03-01)

Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain.
by: Sander Idema, et al.
Published: (2011-01-01)

Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer <it>in vitro</it> and <it>in vivo</it>
by: Zhu Wei, et al.
Published: (2012-05-01)

Adenovirus as a Vector and Oncolytic Virus
by: Wataru Matsunaga, et al.
Published: (2023-06-01)

Designer Oncolytic Adenovirus: Coming of Age
by: Alexander T. Baker, et al.
Published: (2018-06-01)

Oncolytic adenovirus for treatment of malignant ascites
by: Akseli Hemminki, et al.
Published: (2022-09-01)

Increasing the Efficacy of Oncolytic Adenovirus Vectors
by: William S. M. Wold, et al.
Published: (2010-08-01)

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
by: Hanni Uusi-Kerttula, et al.
Published: (2015-11-01)

Intravenous administration of the conditionally replicative adenovirus Ad5-Δ24RGD induces regression of osteosarcoma lung metastases
by: Gerritsen Winald R, et al.
Published: (2008-01-01)

Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells.
by: Sadhak Sengupta, et al.
Published: (2011-03-01)

Oncolytic adenoviruses and immunopeptidomics: a convenient marriage
by: Marc Garcia‐Moure, et al.
Published: (2024-04-01)

Species D Adenoviruses as Oncolytic Viral Vectors
by: Brianna L. Bullard, et al.
Published: (2020-12-01)

Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity
by: Praveensingh B. Hajeri, et al.
Published: (2020-06-01)

Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy
by: Lobke C.M. Hensen, et al.
Published: (2020-09-01)

Bioprocessing of oncolytic group B adenovirus for scalable production
by: Cooper, L
Published: (2014)

In Vivo Tracking for Oncolytic Adenovirus Interactions with Liver Cells
by: Victor A. Naumenko, et al.
Published: (2022-07-01)

Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
by: Daoyuan Xie, et al.
Published: (2023-11-01)

Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy
by: Ee Wern Tan, et al.
Published: (2022-10-01)

Exploring the relationship between cancer metabolism and oncolytic adenoviruses
by: Dyer, A
Published: (2021)

Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses
by: Gabriela Green-Tripp, et al.
Published: (2022-06-01)

Oncolytic Replication of E1b-Deleted Adenoviruses
by: Pei-Hsin Cheng, et al.
Published: (2015-11-01)

Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts
by: Jing Li Huang, et al.
Published: (2016-09-01)

Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.
by: Beatriz Vera, et al.
Published: (2016-01-01)

Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy
by: Mahasa, K, et al.
Published: (2020)

Combining oncolytic adenovirus with radiation – a paradigm for the future of radiosensitization
by: O'Cathail, S, et al.
Published: (2017)

Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer
by: Kaiyi Yang, et al.
Published: (2022-12-01)